Off ‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center

ConclusionsAt our institution, ICI was most commonly prescribed in the relapsed/refractory setting to patients with metastatic disease. The treatment was generally well-tolerated in the pediatric population. The overall response rate was low, and the majority of patients eventually experienced disease progression. A few patients, however, had durable treatment responses. Further studies are needed to identify which pediatric patients are most likely to benefit from ICI.

Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Ajami Gikandi, Susan N. Chi, Kee Kiat Yeo, Allison F. O'Neill, David S. Shulman, Steven G. DuBois, Natalie B. Collins Tags: RESEARCH ARTICLE Source Type: research